Anthem Biosciences (ANTHEM) Share Price Falls for Fourth Consecutive Session
- October 14, 2026
- Posted by: Kunal Singla
- Category: News
Anthem Biosciences Share Price Fall Streak continues in its fourth consecutive session, with the latest traded price at Rs 820.85, down Rs 20.75 or 2.47% from the previous close. The cumulative fall across the streak now stands at 7.05% from Rs 883.1, and the company’s market capitalisation is Rs 47,790 crore. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established.
This longer run matters because it is more informative than a single lower session. A four-session decline can change how readers interpret Anthem Biosciences Share Price Fall Streak, the relative positioning of Anthem Biosciences Share Price Today and the wider stock analysis lens around valuation, sector context and peer comparison. The business remains a large-cap name in healthcare, but the current move has shifted the conversation toward price, multiples and how the latest level compares with the recent starting point.
Anthem Biosciences (ANTHEM) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 820.85 |
| Previous Close | Rs 841.6 |
| Today's Move | -Rs 20.75 (-2.47%) |
| Open | Rs 840 |
| High | Rs 840 |
| Low | Rs 820.45 |
| Market Capitalisation | Rs 47,790 crore |
Anthem Biosciences Share Price Fall Streak opened at Rs 840, touched the day’s high at Rs 840 and slipped to a low of Rs 820.45, with the latest traded price at Rs 820.85 as of 16 October 2026 at 11:11:07 AM IST. The stock therefore traded near the lower end of the day’s range, while the previous close of Rs 841.6 and the day change of Rs -20.75 show the extent of the current session’s decline. Anthem Biosciences Share Price Today is also relevant for readers tracking the move inside a large-cap market-cap profile of Rs 47,790 crore.
In pure price terms, the current level sits Rs 62.25 below the streak base of Rs 883.1, which places the four-session fall in clear view. For anyone following Anthem Biosciences Share Price or Anthem Biosciences Share Price Today, the key point is not a one-off dip but a sequence of lower readings that has carried the stock down across consecutive sessions. That makes the current Anthem Biosciences Share Price Fall Streak more useful as a pattern than as an isolated intraday print, and it leads directly into the fundamental analysis.
What the Consecutive Declines Show
Anthem Biosciences Share Price Fall Streak has now reached the fourth consecutive session, and the cumulative decline of 7.05% is the most important number in that run. The latest session was down 2.47%, which is smaller than the full streak move but still extends the same direction. In a streak context, the reader is not just seeing Anthem Biosciences Share Price Today move lower; the pattern itself is now the event.
The comparison between the starting base of Rs 883.1 and the latest traded price of Rs 820.85 shows how the stock has moved away from the earlier level in a sustained way. For Anthem Biosciences Share Price Fall Streak, that matters because consecutive lower sessions can reshape the way the current valuation and peer comparison are read. The next sections focus on those fundamentals and on whether the present ratios still look aligned with the healthcare universe.
Anthem Biosciences (ANTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 47,790 crore |
| P/E Ratio | 82.35x |
| P/B Ratio | 15.15x |
| ROE | 21.98% |
| ROCE | 29.62% |
| EPS | Rs 10.22 |
| Book Value Per Share | Rs 55.53 |
| Dividend Yield | 0.24% |
Anthem Biosciences (ANTHEM) fundamental metrics show P/E 82.35x, P/B 15.15x, ROE 21.98%, ROCE 29.62%. Taken on their own, these numbers offer context rather than a trading signal.
Anthem Biosciences has a market capitalisation of Rs 47,790.00 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 82.35x, P/B at 15.15x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 21.98% and ROCE of 29.62%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 10.22, book value per share of Rs 55.53, dividend yield of 0.24%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.08x, median ROE of 11.48%, median ROCE of 13.28%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 82.35x |
| Benchmark Median P/E | 31.08x |
| Benchmark Average P/E | 46.65x |
| Benchmark P/E Range | 3.33x to 640x |
| Company P/B Ratio | 15.15x |
| Benchmark Median P/B | 2.87x |
| Benchmark Average P/B | 4.23x |
| Company ROE | 21.98% |
| Benchmark Median ROE | 11.48% |
| Benchmark Average ROE | 10.27% |
| Company ROCE | 29.62% |
| Benchmark Median ROCE | 13.28% |
| Benchmark Average ROCE | 13.16% |
| Company Market Capitalisation | Rs 47,790 crore |
| Benchmark Median Market Cap | Rs 806.56 crore |
| Benchmark Average Market Cap | Rs 13,634.43 crore |
Anthem Biosciences (ANTHEM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Anthem Biosciences (ANTHEM) has a P/E ratio of 82.35x, which is above the benchmark median of 31.08x, a difference of +164.96%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Anthem Biosciences (ANTHEM) has a ROE of 21.98%, which is above the benchmark median of 11.48%, a difference of +91.46%. Anthem Biosciences (ANTHEM) has a ROCE of 29.62%, which is above the benchmark median of 13.28%, a difference of +123.04%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,19,619.69 | 34.92 | 4.88 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,39,714.15 | 82.05 | 13.59 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,74,740.99 | 80.33 | 19.52 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,12,119.43 | 25.21 | 4.22 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,10,007.57 | 99.82 | 19.35 | 18.31 | 18.2 |
Anthem Biosciences (ANTHEM) has a P/E ratio of 82.35x compared with the displayed peer median of 80.33x. The comparison is relative and should not be read as a recommendation. Its ROE of 21.98% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 29.62% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Anthem Biosciences (ANTHEM) has a market capitalisation of Rs 47,790 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Anthem Biosciences
- Anthem Biosciences Share Price Fall Streak has reached the fourth consecutive session, making the pattern more important than any single day move.
- Anthem Biosciences Share Price Today is down 2.47%, with the latest traded price at Rs 820.85.
- The company’s P/E of 82.35 and P/B of 15.15 keep valuation in focus after the price decline.
- ROE of 21.98% and ROCE of 29.62% show strong return metrics in the latest figures.
- The large-cap market capitalisation of Rs 47,790 crore keeps Anthem Biosciences within the upper tier of Healthcare names.
About Anthem Biosciences
Anthem Biosciences operates in Healthcare and the Pharmaceuticals & Drugs industry. For readers following Anthem Biosciences Share Price Fall Streak, the useful context is that the company is large enough to sit well above the benchmark median market capitalisation, yet it is still judged by the same return and valuation ratios as other listed healthcare names. The business context matters because the current move is being read through pricing and comparison, not through any change in the company’s core category.
Anthem Biosciences Share Price analysis is therefore about a high-return healthcare company whose market value has eased over four consecutive sessions. That is the relevant company backdrop for understanding the present streak.
Track Anthem Biosciences Share Price on Univest
Use Anthem Biosciences (ANTHEM) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Readers can track Anthem Biosciences Share Price on Univest for live price movement, key valuation ratios, market capitalisation, 52-week levels and broader market insights. For Anthem Biosciences Share Price Fall Streak, that makes it easier to monitor how the latest traded price compares with the recent base, the sector benchmark and the peer set.
Univest also helps users review Anthem Biosciences Share Price Today alongside core fundamental ratios and company-level stock analysis in one place. That is useful when a decline is pattern-driven across several sessions rather than a single lower print.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Anthem Biosciences Share Price falling today?
Ans. According to Univest data, the stock is trading lower in its fourth consecutive session, with the latest traded price at Rs 820.85. The figures confirm the decline pattern, but they do not establish a company-specific cause.
What is Anthem Biosciences Share Price today?
Ans. Anthem Biosciences Share Price Today is Rs 820.85. It is down Rs 20.75, or 2.47%, from the previous close of Rs 841.6, and it has moved lower across four straight sessions.
How much has Anthem Biosciences Share Price fallen in the streak?
Ans. Anthem Biosciences Share Price Fall Streak is down 7.05% in cumulative terms from the starting base price of Rs 883.1. The current price of Rs 820.85 shows how the decline has built over the run.
What is the market capitalisation of Anthem Biosciences?
Ans. Anthem Biosciences has a market capitalisation of Rs 47,790 crore. That places it well above the benchmark median size in the same-industry comparison set and supports its classification as a large-cap company.
What do Anthem Biosciences valuation ratios show?
Ans. Anthem Biosciences has a P/E of 82.35 and a P/B of 15.15. Those ratios are above the benchmark median and average in the same-industry group, so the stock still trades at a premium to the sector center.
How do Anthem Biosciences profitability metrics look?
Ans. The latest figures show ROE at 21.98% and ROCE at 29.62%, with EPS at Rs 10.22 and book value at Rs 55.53. Those numbers point to strong return generation even after the share price decline.
How does Anthem Biosciences compare with peers?
Ans. Anthem Biosciences Share Price sits beside peers such as Sun Pharma, Divi’s, Torrent, Zydus and Laurus in a high-valuation healthcare group. Its P/E of 82.35 is close to Divi’s and above several others shown.
What sector does Anthem Biosciences belong to?
Ans. Anthem Biosciences operates in Healthcare within the Pharmaceuticals & Drugs industry. In the same-industry benchmark, its P/E, P/B, ROE and ROCE all sit above the benchmark median, which keeps sector context important.
Should investors track Anthem Biosciences Share Price now?
Ans. Anthem Biosciences Share Price is worth tracking because the stock has now fallen for four consecutive sessions. Readers should watch the latest traded price, valuation ratios, market capitalisation and how the streak compares with the peer set.
